Last edition
News about "Nivolumab biosimilar"
Zydus Challenges Delhi HC Order Blocking Sale of Cancer Drug Biosimilar
The single-judge order, issued on July 18, 2025, prohibits Zydus from manufacturing, selling, advertising, importing, or exporting its Nivolumab biosimilar until the final outcome of the case or the expiry of the suit patent on May 2, 2026.
Nivolumab Biosimilar | 25/07/2025 | By Darshana | 339
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members